Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients

BACKGROUND: Low-dose ritonavir (RTV) boosts plasma amprenavir (APV) exposure. Little has been published on the efficacy, tolerability, and safety of APV 600 mg/RTV 100 mg (APV600/RTV) twice daily (BID) compared to APV 1200 mg BID (APV1200). METHODS: ESS40011 was a 24-week, multicenter, open-label, c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Nadler, Jeffrey P, Gathe, Joseph C, Pollard, Richard B, Richmond, Gary J, Liao, Qiming, Griffith, Sandy, Tracey Lancaster, C, Hernandez, Jaime E, Pappa, Keith A
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2003
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC165437/
https://ncbi.nlm.nih.gov/pubmed/12795812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2334-3-10
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados